Mellinghoff, Ingo K.

Publications

Sort by

Co-Author Network

selected publications

Letter: When Less is More: Dexamethasone Dosing for Brain Tumors. Neurosurgery. 2019 Academic Article GET IT
Times cited: 14
Challenges to curing primary brain tumours. Nature reviews. Clinical oncology. 2019 Review GET IT
Times cited: 412
Reply to 'Assembling the brain trust: the multidisciplinary imperative in neuro-oncology'. Nature reviews. Clinical oncology. 2019 Letter GET IT
Phase II trial of an AKT inhibitor (perifosine) for recurrent glioblastoma. Journal of neuro-oncology. 2019 Academic Article GET IT
Times cited: 31
Genomic Correlates of Disease Progression and Treatment Response in Prospectively Characterized Gliomas. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019 Academic Article GET IT
Times cited: 69
Clinical pharmacokinetics and pharmacodynamics of ivosidenib, an oral, targeted inhibitor of mutant IDH1, in patients with advanced solid tumors. Investigational new drugs. 2019 Academic Article GET IT
Times cited: 58
Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Nature medicine. 2019 Academic Article GET IT
Times cited: 696
Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2019 Academic Article GET IT
Times cited: 82
Tracking tumour evolution in glioma through liquid biopsies of cerebrospinal fluid. Nature. 2019 Academic Article GET IT
Times cited: 268
Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nature genetics. 2019 Academic Article GET IT
Times cited: 1996
Phase 1b trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lymphoma. Blood. 2018 Academic Article GET IT
Times cited: 123
Isoform Switching as a Mechanism of Acquired Resistance to Mutant Isocitrate Dehydrogenase Inhibition. 2018 GET IT
Times cited: 107
Validation of postoperative residual contrast-enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastoma. Neuro-oncology. 2018 Academic Article GET IT
Times cited: 49
Metabolic Imaging of the Human Brain with Hyperpolarized ¹³C Pyruvate Demonstrates ¹³C Lactate Production in Brain Tumor Patients. Cancer research. 2018 Academic Article GET IT
Times cited: 146
Multicenter Phase IB Trial of Carboxyamidotriazole Orotate and Temozolomide for Recurrent and Newly Diagnosed Glioblastoma and Other Anaplastic Gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018 Academic Article GET IT
Times cited: 28
In Vivo PET Assay of Tumor Glutamine Flux and Metabolism: In-Human Trial of ¹⁸F-(2S,4R)-4-Fluoroglutamine. Radiology. 2018 Academic Article GET IT
Times cited: 66
EGFR feedback-inhibition by Ran-binding protein 6 is disrupted in cancer. Nature communications. 2017 Academic Article GET IT
Times cited: 17
Prospective Feasibility Trial for Genomics-Informed Treatment in Recurrent and Progressive Glioblastoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2017 Academic Article GET IT
Times cited: 47
Dissecting Glioma Invasiveness in a 3D-Organotypic Model. Trends in molecular medicine. 2017 Comment GET IT
Times cited: 3
Report of safety of pulse dosing of lapatinib with temozolomide and radiation therapy for newly-diagnosed glioblastoma in a pilot phase II study. Journal of neuro-oncology. 2017 Academic Article GET IT
Times cited: 15
Brain Tumors: Challenges and Opportunities to Cure. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017 Article GET IT
Times cited: 20
Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma. Cancer discovery. 2017 Academic Article GET IT
Times cited: 243
Recurrent patterns of DNA copy number alterations in tumors reflect metabolic selection pressures. Molecular systems biology. 2017 Academic Article GET IT
Times cited: 46
Evaluating Cancer of the Central Nervous System Through Next-Generation Sequencing of Cerebrospinal Fluid. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016 Academic Article GET IT
Times cited: 241
Multiplexed immunofluorescence delineates proteomic cancer cell states associated with metabolism. JCI insight. 2016 Academic Article GET IT
Times cited: 301
Prioritization schema for immunotherapy clinical trials in glioblastoma. Oncoimmunology. 2016 Review GET IT
Times cited: 384
MCT1 Modulates Cancer Cell Pyruvate Export and Growth of Tumors that Co-express MCT1 and MCT4. Cell reports. 2016 Academic Article GET IT
Times cited: 146
Molecular Pathways: Isocitrate Dehydrogenase Mutations in Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2016 Review GET IT
Times cited: 143
Integration of 2-hydroxyglutarate-proton magnetic resonance spectroscopy into clinical practice for disease monitoring in isocitrate dehydrogenase-mutant glioma. Neuro-oncology. 2015 Academic Article GET IT
Times cited: 139
Ultrasmall dual-modality silica nanoparticle drug conjugates: Design, synthesis, and characterization. Bioorganic & medicinal chemistry. 2015 Academic Article GET IT
Times cited: 28
T1-Weighted Dynamic Contrast-Enhanced MRI as a Noninvasive Biomarker of Epidermal Growth Factor Receptor vIII Status. AJNR. American journal of neuroradiology. 2015 Academic Article GET IT
Times cited: 40
Cutaneous adverse drug reaction associated with oral temozolomide presenting as dermal and subcutaneous plaques and nodules. 2015 GET IT
Times cited: 7
PI3K pathway inhibition in GBM—is there a signal?. Neuro-oncology. 2015 Editorial Article GET IT
Times cited: 6
Toward precision medicine in glioblastoma: the promise and the challenges. Neuro-oncology. 2015 Review GET IT
Times cited: 151
Glutamine-based PET imaging facilitates enhanced metabolic evaluation of gliomas in vivo. Science translational medicine. 2015 Academic Article GET IT
Times cited: 228
IQGAP1 controls tight junction formation through differential regulation of claudin recruitment. Journal of cell science. 2015 Academic Article GET IT
Times cited: 21
Combined inhibition of MAP kinase and KIT signaling synergistically destabilizes ETV1 and suppresses GIST tumor growth. Cancer discovery. 2015 Academic Article GET IT
Times cited: 95
A kinase-independent function of AKT promotes cancer cell survival. eLife. 2014 Academic Article GET IT
Times cited: 61
Targeted molecular therapies against epidermal growth factor receptor: past experiences and challenges. Neuro-oncology. 2014 Review GET IT
Times cited: 83
A correlative optical microscopy and scanning electron microscopy approach to locating nanoparticles in brain tumors. Micron (Oxford, England : 1993). 2014 Academic Article GET IT
Times cited: 26
Brain Malignancy Steering Committee clinical trials planning workshop: report from the Targeted Therapies Working Group. Neuro-oncology. 2014 Review GET IT
Times cited: 25
Phase II study of bevacizumab, temozolomide, and hypofractionated stereotactic radiotherapy for newly diagnosed glioblastoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2014 Academic Article GET IT
Times cited: 78
ZFHX4 interacts with the NuRD core member CHD4 and regulates the glioblastoma tumor-initiating cell state. Cell reports. 2014 Academic Article GET IT
Times cited: 86
mTOR complex 2 controls glycolytic metabolism in glioblastoma through FoxO acetylation and upregulation of c-Myc. Cell metabolism. 2013 Academic Article GET IT
Times cited: 298
An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science (New York, N.Y.). 2013 Academic Article GET IT
Times cited: 887
Recurrent somatic mutation of FAT1 in multiple human cancers leads to aberrant Wnt activation. Nature genetics. 2013 Academic Article GET IT
Times cited: 265
Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma. Neuro-oncology. 2012 Academic Article GET IT
Times cited: 87
Imaging tumor burden in the brain with 89Zr-transferrin. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2012 Academic Article GET IT
Times cited: 35
Akt phosphorylates the transcriptional repressor bmi1 to block its effects on the tumor-suppressing ink4a-arf locus. Science signaling. 2012 Academic Article GET IT
Times cited: 41
Integrin αvβ3-targeted IRDye 800CW near-infrared imaging of glioblastoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2012 Academic Article GET IT
Times cited: 59
Glucose deprivation activates a metabolic and signaling amplification loop leading to cell death. Molecular systems biology. 2012 Academic Article GET IT
Times cited: 143
A brain tumor molecular imaging strategy using a new triple-modality MRI-photoacoustic-Raman nanoparticle. Nature medicine. 2012 Academic Article GET IT
Times cited: 878
Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors. Cancer discovery. 2012 Academic Article GET IT
Times cited: 246
IDH mutation and neuroglial developmental features define clinically distinct subclasses of lower grade diffuse astrocytic glioma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2012 Academic Article GET IT
Times cited: 114
IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature. 2012 Academic Article GET IT
Times cited: 1461
IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature. 2012 Academic Article GET IT
Times cited: 1441
A mathematical methodology for determining the temporal order of pathway alterations arising during gliomagenesis. PLoS computational biology. 2012 Academic Article GET IT
Times cited: 52
Cancer drug development. Preface. Current topics in microbiology and immunology. 2012 Article GET IT
Will kinase inhibitors make it as glioblastoma drugs?. Current topics in microbiology and immunology. 2012 Review GET IT
Times cited: 20
Genomic dissection of the epidermal growth factor receptor (EGFR)/PI3K pathway reveals frequent deletion of the EGFR phosphatase PTPRS in head and neck cancers. Proceedings of the National Academy of Sciences of the United States of America. 2011 Academic Article GET IT
Times cited: 82
Virchow 2011 or how to ID(H) human glioblastoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011 Editorial Article GET IT
Times cited: 17
An LXR agonist promotes glioblastoma cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR-dependent pathway. Cancer discovery. 2011 Academic Article GET IT
Times cited: 271
18F-fluorodeoxy-glucose positron emission tomography marks MYC-overexpressing human basal-like breast cancers. Cancer research. 2011 Academic Article GET IT
Times cited: 103
Signal transduction inhibitors and antiangiogenic therapies for malignant glioma. Glia. 2011 Review GET IT
Times cited: 28
Epidermal growth factor receptor inhibitors in oncology. Current opinion in oncology. 2010 Review GET IT
Times cited: 45
Tracing cancer networks with phosphoproteomics. Nature biotechnology. 2010 Academic Article GET IT
Times cited: 14
A mathematical framework to determine the temporal sequence of somatic genetic events in cancer. Proceedings of the National Academy of Sciences of the United States of America. 2010 Academic Article GET IT
Times cited: 95
The phosphatase and tensin homolog regulates epidermal growth factor receptor (EGFR) inhibitor response by targeting EGFR for degradation. Proceedings of the National Academy of Sciences of the United States of America. 2010 Academic Article GET IT
Times cited: 93
EGFR signaling through an Akt-SREBP-1-dependent, rapamycin-resistant pathway sensitizes glioblastomas to antilipogenic therapy. Science signaling. 2009 Academic Article GET IT
Times cited: 261
Somatic mutations of the Parkinson's disease-associated gene PARK2 in glioblastoma and other human malignancies. Nature genetics. 2009 Academic Article GET IT
Times cited: 299
Inhibition of the phosphatidylinositol 3-kinase-Akt pathway enhances gamma-2 herpesvirus lytic replication and facilitates reactivation from latency. The Journal of general virology. 2009 Academic Article GET IT
Times cited: 38
PTEN dosage is essential for neurofibroma development and malignant transformation. Proceedings of the National Academy of Sciences of the United States of America. 2009 Academic Article GET IT
Times cited: 89
Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer. The Journal of clinical investigation. 2009 Academic Article GET IT
Times cited: 346
14-3-3sigma and p21 synergize to determine DNA damage response following Chk2 inhibition. Cell cycle (Georgetown, Tex.). 2009 Academic Article GET IT
Times cited: 6
Proteasomal and genetic inactivation of the NF1 tumor suppressor in gliomagenesis. Cancer cell. 2009 Academic Article GET IT
Times cited: 112
The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers. Proceedings of the National Academy of Sciences of the United States of America. 2009 Academic Article GET IT
Times cited: 212
Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy. Nature biotechnology. 2008 Academic Article GET IT
Times cited: 200
Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS medicine. 2008 Academic Article GET IT
Times cited: 479
Development of a real-time RT-PCR assay for detecting EGFRvIII in glioblastoma samples. Clinical cancer research : an official journal of the American Association for Cancer Research. 2008 Academic Article GET IT
Times cited: 80
Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proceedings of the National Academy of Sciences of the United States of America. 2007 Academic Article GET IT
Times cited: 834
Why do cancer cells become "addicted" to oncogenic epidermal growth factor receptor?. PLoS medicine. 2007 Review GET IT
Times cited: 5
Identification of the JNK signaling pathway as a functional target of the tumor suppressor PTEN. Cancer cell. 2007 Academic Article GET IT
Times cited: 201
Relationship between survival and edema in malignant gliomas: role of vascular endothelial growth factor and neuronal pentraxin 2. Clinical cancer research : an official journal of the American Association for Cancer Research. 2007 Academic Article GET IT
Times cited: 94
High-throughput oncogene mutation profiling in human cancer. Nature genetics. 2007 Academic Article GET IT
Times cited: 885
PTEN-mediated resistance to epidermal growth factor receptor kinase inhibitors. Clinical cancer research : an official journal of the American Association for Cancer Research. 2007 Review GET IT
Times cited: 109
Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain. PLoS medicine. 2006 Academic Article GET IT
Times cited: 268
Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells. Cancer research. 2006 Academic Article GET IT
Times cited: 211
Inferring loss-of-heterozygosity from unpaired tumors using high-density oligonucleotide SNP arrays. PLoS computational biology. 2006 Academic Article GET IT
Times cited: 128
Progression of prostate cancer by synergy of AKT with genotropic and nongenotropic actions of the androgen receptor. Proceedings of the National Academy of Sciences of the United States of America. 2006 Academic Article GET IT
Times cited: 136
Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nature medicine. 2005 Academic Article GET IT
Times cited: 547
Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. The New England journal of medicine. 2005 Academic Article GET IT
Times cited: 1239
Monitoring antiproliferative responses to kinase inhibitor therapy in mice with 3'-deoxy-3'-18F-fluorothymidine PET. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2005 Academic Article GET IT
Times cited: 103
HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability. Cancer cell. 2004 Academic Article GET IT
Times cited: 288
TORward AKTually useful mouse models. Nature medicine. 2004 Comment GET IT
Times cited: 16
AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression. The Journal of biological chemistry. 2003 Academic Article GET IT
Times cited: 306
Growth inhibitory effects of the dual ErbB1/ErbB2 tyrosine kinase inhibitor PKI-166 on human prostate cancer xenografts. Cancer research. 2002 Academic Article GET IT
Times cited: 85
The emergence of resistance to targeted cancer therapeutics. Pharmacogenomics. 2002 Review GET IT
Times cited: 25
Treatment of Scedosporium apiospermum brain abscesses with posaconazole. 2002 GET IT
Times cited: 112
Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proceedings of the National Academy of Sciences of the United States of America. 2001 Academic Article GET IT
Times cited: 914
Buerger disease or arsenic intoxication?. Archives of internal medicine. 2001 Letter GET IT
The role of cocaine in the etiology of Buerger disease is questionable. Archives of internal medicine. 2001 Letter GET IT
Times cited: 1
Cocaine and Buerger disease: is there a pathogenetic association? 2000 GET IT
Times cited: 38
Early events in Epstein-Barr virus genome expression after activation: regulation by second messengers of B cell activation. Virology. 1991 Academic Article GET IT
Times cited: 40
Effect of genistein, a tyrosine kinase inhibitor, on latent EBV activation induced by cross-linkage of membrane IgG in Akata B cells. Journal of immunology (Baltimore, Md. : 1950). 1991 Academic Article GET IT
Times cited: 22

more ...

less ...

Background

education and training

M.D., Technical University of Munich, Faculty of Medicine (Germany) 1993

Contact

full name

Ingo K. Mellinghoff

primary email

mellingi@mskcc.org

VIVO Weill Cornell Medical College

Ingo K. Mellinghoff Professor of Neurology

Publications

selected publications

Background

education and training

Contact

full name

primary email

Phone

Publications

selected publications

Background

education and training

Contact

full name

primary email